Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 11, 2021

Romidepsin Plus CHOP vs CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
J. Clin. Oncol 2021 Nov 29;[EPub Ahead of Print], E Bachy, V Camus, C Thieblemont, D Sibon, RO Casasnovas, L Ysebaert, G Damaj, S Guidez, GM Pica, WS Kim, ST Lim, M André, AM García-Sancho, MJ Penarrubia, PB Staber, J Trotman, A Hüttmann, V Stefoni, A Re, P Gaulard, MH Delfau-Larue, L de Leval, M Meignan, J Li, F Morschhauser, R Delarue

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading